<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00640328</url>
  </required_header>
  <id_info>
    <org_study_id>115102</org_study_id>
    <nct_id>NCT00640328</nct_id>
    <nct_alias>NCT01526993</nct_alias>
  </id_info>
  <brief_title>Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients</brief_title>
  <acronym>OMS115102</acronym>
  <official_title>A Double-blind, Randomized, Placebo Controlled, Multicenter, Dose-finding Trial of Ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial consists of a dose escalation, to establish the safety of ofatumumab in RRMS
      patients. A 48-week treatment period followed by an individualized follow-up period until
      normalization of peripheral B-cell counts or Immunoglobulin G (IgG) levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial consists of two phases, a 48 week treatment period, followed by an individualized
      treatment period of up to two years.

      Patients are treated in cohorts of increasing doses (100 mg, 300 mg and 700 mg) with 12
      patients in each dose cohort. Within each cohort patients are randomized asymmetrically in a
      2:1 ratio such that eight patients will receive ofatumumab and four patients will receive
      placebo. After 24 weeks the patients randomized to placebo will be treated with the active
      dose for the cohort. For blinding purposes, patients randomized to the active dose will be
      treated with placebo after 24 weeks. Thus, each patient will receive two administrations of
      trial product with 24 weeks follow-up resulting in a total treatment period of 48 weeks
      duration. An Independent Data Monitoring Committee (IDMC) will review and evaluate the safety
      data of each cohort, a minimum of 4 weeks data including the week 4 Magnetic Resonance
      Imaging (MRI) from at least 10 patients, to consider if progression to the next higher dose
      cohort is acceptable.

      The trial product is administered as two infusions separated by two weeks. Clinical
      assessment and Gadolinium enhanced (Gd-enhanced) MRI scan will be performed at weeks -4, 0,
      2, 4, and every 4 weeks until week 48. The MRI scan at week 2 is carried out for safety
      assessment prior to administering the second infusion in the first treatment course. When
      patients in all dose cohorts have been dosed and have had week 4 MRI scans performed, an IDMC
      will review all available safety data.

      After completion of week 48 patients will be followed to monitor B-cell and IgG
      normalization. B-cell levels will be monitored every 12 weeks until CD19+ cells have returned
      to baseline level (Visit 3) or normalized level. If the B-cell levels are not normalized
      after two years the patient should be followed until either the IgG or the B-cell levels are
      normalized (see Section 9.2.4 for details). During this period Gd-enhanced MRI follow up
      scans will be performed every 12 weeks to evaluate potential rebound, safety and for
      Progressive Multifocal Leukoencephalopathy (PML) monitoring.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Any Adverse Event</measure>
    <time_frame>First Treatment Period (FTP): From Visit 3 (Week 0) up to Visit 10 (Week 24); Second Treatment Period (STP): From Visit 10 (Week 24) up to Visit 17 (Week 48); IFUP: up to Visit 26 (Week 104)</time_frame>
    <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A list of all adverse events is reported in the &quot;Other (Non-Serious) Adverse Events&quot; section. Non-serious AEs were not collected during the Individualized Follow-up Period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With the Indicated Critical Adverse Events (CAEs)</measure>
    <time_frame>FTP: From Visit 3 (Week 0) up to Visit 10 (Week 24); STP: From Visit 10 (Week 24) up to Visit 17 (Week 48); IFUP: up to Visit 26 (Week 104)</time_frame>
    <description>A CAE=treatment-related (TR) grade (G) &gt;=3 AE on day of infusion (inf.) preventing inf. to be resumed, a TR G 3 bronchospasm during 1 inf., an AE whose severity becomes G 3 for the third time during 1 inf., infections reported as serious, a TR neurological event consistent with progressive multifocal leukoencephalopathy (PML), any malignancy, and any fatal adverse drug reaction. AE severity (assessed as G 1-5) was classified using the Common Terminology Criteria for Adverse Events v3.0: G 1=mild AE; G 2=moderate AE; G 3=severe AE; G 4=life-threatening or disabling AE; G 5=death related to AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Negative or Unconfirmed Human Anti-human Antibodies (HAHA) in Which Concentrations of Ofa Were Below 500 Nanograms Per Milliliter (ng/ml)</measure>
    <time_frame>Visit 3 (Week 0), Visit 10 (Week 24), Visit 17 (Week 48) or early withdrawal (EW), and Visit 26 (Week 104)</time_frame>
    <description>Participants are checked for negative (or a lack of) HAHA at Baseline, and then throughout the study, to ensure that the investigational product is not causing HAHA development. Participants with concentrations of Ofa that are missing or are above 500 nanograms per milliliter (ng/mL) are considered to have unconfirmed HAHA results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Physical Examination Findings</measure>
    <time_frame>FTP: From Visit 3 (Week 0) up to Visit 10 (Week 24); STP: From Visit 10 (Week 24) up to Visit 17 (Week 48); IFUP: up to Visit 26 (Week 104)</time_frame>
    <description>The investigator performed the physical examination, which included but was not limited to: general appearance and the following body systems: lymph nodes, mouth and throat, lungs, cardiovascular, abdomen, extremities, muscular-skeletal, neurological (apart from multiple sclerosis [a brain and spinal cord disease]), and skin. All abnormal clinically relevant findings such as vein problems (venous varices), disorder of the vertebral column (vertebropathy), increased hearing loss, post operative mark (scar), and chronic skin disorder with no sweat and itching (anhidrotic eczema) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Basophils, Eosinophils, Leukocytes, Monocytes, Lymphocytes, Neutrophils, and Platelet Count at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</measure>
    <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48); IFUP: Visit 26 (Week 104)</time_frame>
    <description>Blood samples of participants were collected for hematology assessment. Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in basophils, eosinophils, leukocytes, monocytes, lymphocytes, neutrophils, and platelets count was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Week 104 for the IFUP minus the value at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Erythrocyte Count at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</measure>
    <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48); IFUP: Visit 26 (Week 104)</time_frame>
    <description>Blood samples of participants were collected for assessment of erythrocyte count. Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in erythrocyte count was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Visit 26 (Week 104) for the IFUP minus the value at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Hematocrit at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</measure>
    <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48); IFUP: Visit 26 (Week 104)</time_frame>
    <description>Blood samples of participants were collected for hematocrit assessment. Hematocrit is the percentage of blood volume (BV) that is occupied by red blood cells (RBCs). Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in hematocrit was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Visit 26 (Week 104) for the IFUP minus the value at Baseline. Hematocrit is measured as a percentage, i.e., volume (V) of red blood cells per volume of blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Hemoglobin Count at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</measure>
    <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48); IFUP: Visit 26 (Week 104)</time_frame>
    <description>Blood samples of participants were collected for assessment of hemoglobin count. Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in hemoglobin was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Visit 26 (Week 104) for the IFUP minus the value at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Albumin at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</measure>
    <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48); IFUP: VIsit 26 (Week 104)</time_frame>
    <description>Blood samples of participants were collected for assessment of albumin count. Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 104 for the IFUP) in albumin was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Visit 26 (Week 104) for the IFUP minus the value at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Alkaline Phosphatase, Aspartate Aminotransferase (AST), and Alanine Transaminase (ALT) at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</measure>
    <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48); IFUP: up to Visit 26 (Week 104)</time_frame>
    <description>Blood samples of participants were collected for the assessment of alkaline phosphatase, AST, and ALT. Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Visit 26 (Week 104) for the IFUP minus the value at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Bicarbonate, Glucose, Potassium, Sodium, and Urea at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</measure>
    <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48); IFUP: up to Visit 26 (Week 104)</time_frame>
    <description>Blood samples of participants were collected for the assessment of bicarbonate, glucose, potassium, and urea. Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Visit 26 (Week 104) for the IFUP minus the value at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline (Week 0 for the FTP,Week 24 for the STP, and Week 0 for the IFUP) in Bilirubin and Creatinine at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</measure>
    <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48); IFUP: up to Visit 26 (Week 104)</time_frame>
    <description>Blood samples of participants were collected for the assessment of bilirubin and creatinine. Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Visit 26 (Week 104) for the IFUP minus the value at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Immunoglobins at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</measure>
    <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48); IFUP: up to Visit 26 (Week 104)</time_frame>
    <description>Blood samples of participants were collected for the assessment of antibodies produced by B-cells (immunoglobins): immunoglobulin A, immunoglobin G, and immunoglobin M. Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Visit 26 (Week 104) for the IFUP minus the value at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline (Week 0 for the FTP and Week 24 for the STP) in Blood Pressure (BP) at Week 24 (FTP) and Week 48 (STP)</measure>
    <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48)</time_frame>
    <description>Maximum (systolic) and minimum (diastolic) BP were assessed prior to infusion. Change from Baseline (Week 0 for the FTP and Week 24 for the STP) was calculated as the value at Visit 10 (Week 24) for the FTP and the value at Visit 17 (Week 48) for the STP minus the value at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline (Week 0 for the FTP and Week 24 for the STP) in Pulse Rate at Week 24 (FTP) and Week 48 (STP)</measure>
    <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48)</time_frame>
    <description>The pulse rate of each participant was assessed prior to infusion. Change from Baseline (Week 0 for the FTP and Week 24 for the STP) was calculated as the value at Visit 10 (Week 24) for the FTP and the value at Visit 17 (Week 48) for the STP minus the value at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline (Week 0 for the FTP and Week 24 for the STP) in Temperature at Week 24 (FTP) and Week 48 (STP)</measure>
    <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48)</time_frame>
    <description>The temperature of each participant was assessed prior to infusion. Change from Baseline (Week 0 for the FTP and Week 24 for the STP) was calculated as the value at Visit 10 (Week 24) for the FTP and the value at Visit 17 (Week 48) for the STP minus the value at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline (Week 0 for the FTP and Week 24 for the STP) in Complement Activation (CH50) at Week 24 (FTP) and Week 48 (STP)</measure>
    <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48)</time_frame>
    <description>Blood samples of participants were collected for CH50 prior to and 2 hours after dosing, and the samples were sent to a Central Laboratory for analysis: Bio Analytical Research Corporation (BARC). Change from Baseline (Week 0 for the FTP; Week 24 for the STP) was calculated as the value at Weeks 24 (FTP) and 48 (STP) minus the value at Baseline. Ofa depletes (induces the cell death of) B cells. When Ofa binds to a B cell, it induces complement CH50, which in turn causes cell death via cytotoxicity. Therefore, the CH50 levels were measured to ensure that CH50 was being appropriately activated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of the Indicated Types of Lesions (Ls) Assessed Per Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>FTP: From Visit 3 (Week 0) up to Visit 10 (Week 24); STP: From Visit 10 (Week 24) up to Visit 17 (Week 48); IFUP: up to Visit 26 (Week 104)</time_frame>
    <description>The MRI scan was performed prior to dosing and could be performed up to 4 days prior to Visits 3 and 10. An IDMC reviewed the data. T1 enhancing Ls are enhanced by gadolinium, are considered representative of disease activity/inflammation, and may signify a relapse. Measurement of these Ls is comparative from visit to visit. &quot;Total T1 enhancing Ls&quot; represent the total of the new T1 enhancing Ls over the entire study period. T2 L measurements measure all Ls on the brain in terms of volume and size, measuring for new or enlarging Ls. T1 hypointensive Ls are areas of permanent damage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Volume of T2 Lesions at Week 24 and Week 48</measure>
    <time_frame>Visit 10 (Week 24) and Visit 17 (Week 48)</time_frame>
    <description>The MRI scan should be performed prior to dosing and can be performed up to 4 days prior to Visits 3 and 10. An IDMC reviewed the data. The volume of T2 lesions was not a cumulative volume, but the volume measured at Visit 10 and Visit 17. T2 lesion measurements measure all lesions on the brain in terms of volume and size, measuring for new lesions or enlarging lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ofa Drug Concentration After the First (Visit 3), Second (Visit 4), Third (Visit 10), and Fourth (Visit 11) Intravenous (i.v.) Infusions</measure>
    <time_frame>Visit 3 (Week 0), Visit 4 (Week 2), Visit 10 (Week 24), and Visit 11 (Week 26). Samples were drawn predose, immediately following the end of infusion, 10 minutes after infusion, 1 hour after infusion, and 2 hours after infusion.</time_frame>
    <description>The peripheral blood for each participant was collected and analyzed for the concentration of the drug in serum. There were four infusions in the study; the third infusion at Visit 10 represents the first infusion of the second treatment period (Weeks 24-48). Data are presented for the predose concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Maximum Observed Plasma Concentration (Cmax) After the First (Visit 3), Second (Visit 4), Third (Visit 10), and Fourth (Visit 11) i.v. Infusions</measure>
    <time_frame>Visit 3 (Week 0), Visit 4, (Week 2), Visit 10 (Week 24), and Visit 11 (Week 26). Samples were drawn predose, immediately following the end of infusion, 10 minutes after infusion, 1 hour after infusion, and 2 hours after infusion.</time_frame>
    <description>The peripheral blood for each participant was collected and analyzed for Cmax after the first, second, third, and fourth i.v. infusions. Assessment was performed using the noncompartmental method (this analysis is highly dependent on the estimation of total drug exposure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Time Point (AUC(0-t)) After the First (Visit 3), Second (Visit 4), Third (Visit 10), and Fourth (Visit 11) i.v. Infusions</measure>
    <time_frame>Visit 3 (Week 0), Visit 4 (Week 2), Visit 10 (Week 24), and Visit 11 (Week 26). Samples were drawn predose, immediately following the end of infusion, 10 minutes after infusion, 1 hour (hr) after infusion, and 2 hours after infusion.</time_frame>
    <description>The peripheral blood for each participant was collected and analyzed to estimate the area under the plasma concetration-time curve, AUC(0-t), and was assessed using the non-compartmental method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Cmax (Tmax) After the First (Visit 3), Second (Visit 4), Third (Visit 10), and Fourth (Visit 11) i.v. Infusions</measure>
    <time_frame>Visit 3 (Week 0), Visit 4 (Week 2),Visit 10 (Week 24), and Visit 11 (Week 26). Samples were drawn predose, immediately following the end of infusion, 10 minutes after infusion, 1 hour after infusion, and 2 hours after infusion.</time_frame>
    <description>The peripheral blood for each participant was collected and analyzed for tmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of Ofa Over the Course of Weeks 0-2 and 24-26</measure>
    <time_frame>Weeks 0-2 and 24-26</time_frame>
    <description>The peripheral blood for each participant was collected and analyzed for clearance. Clearance is the measure of efficiency with which a drug is irreversibly removed form the body. The average clearance over the course of Weeks 0-2 and 24-26 is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Volume of Distribution at Steady State (Vss) of Ofatumumab Over the Course of Weeks 0-2 and 24-26</measure>
    <time_frame>Weeks 0-2 and 24-26</time_frame>
    <description>The peripheral blood for each participant was collected and analyzed for Vss. The average Vss over the course of Weeks 0-2 and 24-26 is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half Life (t1/2) of Ofatumumab in the Terminal Elimination Phase Over the Course of Weeks 0-2 and 24-26</measure>
    <time_frame>Weeks 0-2 and 24-26</time_frame>
    <description>The peripheral blood for each participant was collected and analyzed for half life. Half life is defined as the period of time required for the amount of drug in the body to be reduced by half. The average t1/2 over the course of Weeks 0-2 and 24-26 is reported.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Cohort 1.1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg ofatumumab then placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1.2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo then 100mg ofatumumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2.1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg ofatumumab then placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2.2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo then 300mg ofatumumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3.1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>700mg ofatumumab then placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3.2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo then 700mg ofatumumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ofatumumab 100</intervention_name>
    <description>100mg</description>
    <arm_group_label>Cohort 1.2</arm_group_label>
    <arm_group_label>Cohort 1.1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ofatumumab 300</intervention_name>
    <description>300mg</description>
    <arm_group_label>Cohort 2.1</arm_group_label>
    <arm_group_label>Cohort 2.2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ofatumumab 700</intervention_name>
    <description>700mg</description>
    <arm_group_label>Cohort 3.2</arm_group_label>
    <arm_group_label>Cohort 3.1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>Cohort 1.2</arm_group_label>
    <arm_group_label>Cohort 2.1</arm_group_label>
    <arm_group_label>Cohort 2.2</arm_group_label>
    <arm_group_label>Cohort 3.2</arm_group_label>
    <arm_group_label>Cohort 1.1</arm_group_label>
    <arm_group_label>Cohort 3.1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with definite diagnosis of relapsing-remitting MS according to McDonald
             criteria

          -  Patients with:

          -  At least two confirmed relapses within the last 24 months or

          -  At least one confirmed relapse within the last 12 months or

          -  One confirmed relapse between 12 and 24 months prior to screening, and at least one
             documented T1 Gd-enhancing lesion on an MRI performed within 12 months prior to
             screening.

          -  Patients with disability equivalent to Expanded Disability Status Scale (EDSS) score
             of 0-5.0 (both included) at screening

          -  Neurologically stable patients with no evidence of relapse for at least 30 days prior
             to start of Screening and during the Screening Phase

          -  Female patients must be either post-menopausal, surgically incapable of bearing
             children or practicing an acceptable method of birth control e.g. hormonal
             contraceptives, intrauterine device, spermicide and barrier as long as they are on
             trial medication and for a period of 1 year following the last infusion of trial drug.
             Females of childbearing potential must have a negative pregnancy test at screening
             visit prior to entry into the treatment period

          -  Following receipt of verbal and written information about the trial, the patient must
             provide signed informed consent before any trial related activity is carried out.

        Exclusion Criteria:

          -  Diagnosis of Secondary Progressive Multiple Sclerosis (SPMS), Primary Progressive
             Multiple Sclerosis (PPMS) or Progressive Relapsing Multiple Sclerosis (PRMS) or
             Neuromyelitis optica

          -  Neurological findings consistent with Progressive Multifocal Leukoencephalopathy (PML)
             or confirmed PML

          -  Findings on brain MRI scan indicating any other clinically significant brain
             abnormality other than MS

          -  Patients unable to undergo MRI scans (e.g. due to pacemaker, severe claustrophobia,
             hypersensitivity to contrast media) or who lack adequate peripheral venous access

          -  Patients who have had the following treatments:

          -  Lymphocyte-depleting therapies (e.g. alemtuzumab (CampathÂ®), anti-Cluster of
             Differentiation (CD4), cladribine, total body irradiation, bone marrow
             transplantation), mitoxantrone or cyclophosphamide at any time

          -  Anti-CD20 treatments or any monoclonal antibodies at any time

          -  Immunoglobulin, azathioprine, cyclosporine, tacrolimus or other immunosuppressive
             agents, immunomodulatory agents or plasma exchange within six months prior to
             randomization in the trial apart from Glatiramer Acetate and Interferon Beta (IFN-b).

          -  Glatiramer Acetate or IFN-b within three months prior to the randomization in the
             trial.

          -  Glucocorticoids or Adrenocorticotropic Hormone (ACTH) within one month prior to the
             screening in the trial.

          -  Receipt of a live vaccine within one month prior to screening in the trial.

          -  Plasmapheresis for treatment of relapses within 2 months prior to randomization in the
             trial.

          -  Initiation of therapy with Statins or hormone replacement treatment within one month
             or less prior to screening in the trial.

          -  Patients who have received other disease modifying therapies for MS may be allowed on
             a case to case basis after discussion with the sponsors medical monitor

          -  Past or current history of medically significant adverse effects (including allergic
             reactions) from:

          -  Cetirizine

          -  Prednisolone

          -  Paracetamol/acetaminophen

          -  Plasma proteins or a known hypersensitivity to components of the investigational
             product.

          -  Past or current malignancy, except for

          -  Cervical carcinoma Stage 1B or less

          -  Non-invasive basal cell and squamous cell skin carcinoma

          -  Cancer diagnoses with a complete response of a duration of &gt; 5 years. Patients with a
             prior history of hematological malignancies are excluded regardless of response

          -  Clinically significant cardiac disease, including acute myocardial infarction within
             six months from screening, unstable angina, congestive heart failure, previous venous
             or arterial thrombosis or arrhythmia requiring therapy.

          -  Electrocardiogram (ECG) showing significant abnormality that the treating investigator
             determines may jeopardize the subject's health (i.e. acute ischemia, left bundle
             branch or bifascicular block)

          -  Significant concurrent, uncontrolled medical condition including, but not limited to,
             renal, hepatic, hematological, gastrointestinal, endocrine, immunodeficiency syndrome,
             pulmonary, cerebral, psychiatric or neurological disease which may impair their
             reliable participation in the trial or necessitate the use of medication not allowed
             by this protocol.

          -  History of severe, clinically significant Central Nervous System (CNS) trauma (e.g.
             cerebral contusion, spinal cord compression) or a history or presence of myelopathy
             due to spinal cord compression by disk or vertebral disease

          -  Chronic or ongoing active infectious disease requiring systemic treatment such as, but
             not limited to, chronic renal infection, chronic chest infection with bronchiectasis,
             tuberculosis and active Hepatitis C. Any previous serious infections should be
             discussed with the sponsors medical monitor (e.g. opportunistic or atypical
             infections)

          -  Female patients who are pregnant or nursing.

          -  Use of an investigational drug or other experimental therapy for a condition other
             than MS within 4 weeks prior to screening. Any prior use of an investigational drug or
             other experimental therapy for MS at any time should be discussed with the medical
             monitor.

          -  Current participation in any other interventional clinical trial. Participation in
             non-interventional trial requires approval of the protocol by the sponsor

          -  Serum vitamin B12 below lower limit of normal

          -  Positive polymerase chain reaction (PCR) screening for John Cunningham Virus (JC
             Virus) as measured by qualitative plasma and/or white blood cell JCV DNA

          -  Serologic evidence of Hepatitis B (HB) infection based on the results of testing for
             Hepatitis B Surface Antigen (HBsAg), anti- Hepatitis B Core (HBc) and anti- Hepatitis
             B Surface (HBs) antibodies with eligibility based on the results as follows:

          -  Patients positive for HBsAg are excluded

          -  Patients negative for HBsAg but positive for both anti-HBc and anti-HBs antibodies
             (indicating past infection) are eligible

          -  Patients negative for HBsAg and anti-HBc antibody but positive for anti-HBs antibody
             (indicating past vaccination) are eligible

          -  Patients negative for HBsAg and anti-HBs antibody but positive for anti-HBc antibody
             will require clarification of their status by testing for HB DNA, which if positive
             will exclude the patient from participation

          -  Patient with documented vaccination against Hepatitis B (primary and secondary
             immunization and booster) will be considered eligible for the trial.

          -  Positive serology for HIV

          -  Screening laboratory values:

          -  White Blood Cell (WBC) &lt; 3.0 x 109/L

          -  Neutrophils &lt; 2 x 109/L

          -  Platelets &lt; 100 x 109/L

          -  Circulating IgG level &lt; lower limit of normal (according to central laboratory range)

          -  Serum Alanine Aminotransferase (S-ALAT) &gt; 2.5 times the upper limit of normal
             (according to central laboratory range)

          -  Serum Alpha Fetoprotein (S-AP) &gt; 2.0 times the upper limit of normal (according to
             central laboratory range)

          -  Serum Aspartate Aminotransferase (ASAT) &gt;3.0 times the upper limit of normal
             (according to central laboratory range)

          -  Bilirubin &gt; 1.5 times the upper limit of normal (according to central laboratory
             range)

          -  S-creatinine &gt; the upper limit of normal (according to central laboratory range)

          -  CD4 count &lt;500 cells/mm3, CD4:CD8 &lt;0.9

          -  Patients known or suspected of not being able to comply with a trial protocol (e.g.
             due to alcoholism, drug dependency or psychological disorder).

          -  Positive test for Hepatitis C antibody confirmed with a Hepatitis C real time (RT) PCR
             assay.

        Patients who are positive for Hepatitis C antibody and negative when the Hepatitis C RT PCR
        assay is performed will be eligible for the study. Patients who are positive for Hepatitis
        C antibody and have a positive or indeterminate result when the Hepatitis C RT PCR assay is
        performed will not be eligible for the study.

          -  Positive test results for tuberculosis using the QuantiFERON test and/or Chest X-ray
             findings suggestive of tuberculosis (TB). For patients who have had a Chest X-ray
             performed within the past 6 months without any findings indicative of TB, QuantiFERON
             test alone may be performed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Former Serbia and Montenegro</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2008</study_first_submitted>
  <study_first_submitted_qc>March 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2008</study_first_posted>
  <results_first_submitted>November 1, 2012</results_first_submitted>
  <results_first_submitted_qc>December 3, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 4, 2012</results_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsing forms of multiple sclerosis</keyword>
  <keyword>ofatumumab</keyword>
  <keyword>multiple sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ofatumumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>In all 3 dose cohorts, participants in the active/placebo group received treatment with ofatumumab during the First Treatment Period and placebo during the Second Treatment Period. Participants in the placebo/active group received treatment with placebo during the First Treatment Period and ofatumumab during the second treatment period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
          <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
        </group>
        <group group_id="P2">
          <title>300 mg Ofa/Matching Placebo</title>
          <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
        </group>
        <group group_id="P3">
          <title>700 mg Ofa/Matching Placebo</title>
          <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
        </group>
        <group group_id="P4">
          <title>Matching Placebo/100 mg Ofa</title>
          <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
        </group>
        <group group_id="P5">
          <title>Matching Placebo/300 mg Ofa</title>
          <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
        </group>
        <group group_id="P6">
          <title>Matching Placebo/700 mg Ofa</title>
          <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Treatment Period (Weeks 0-24)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Treatment Period (Weeks 24-48)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>IFUP (Week 48 to Individual Termination)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Recommended - Informed Consent Form</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
          <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
        </group>
        <group group_id="B2">
          <title>300 mg Ofa/Matching Placebo</title>
          <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
        </group>
        <group group_id="B3">
          <title>700 mg Ofa/Matching Placebo</title>
          <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
        </group>
        <group group_id="B4">
          <title>Matching Placebo/100 mg Ofa</title>
          <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
        </group>
        <group group_id="B5">
          <title>Matching Placebo/300 mg Ofa</title>
          <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
        </group>
        <group group_id="B6">
          <title>Matching Placebo/700 mg Ofa</title>
          <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="4"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.0" spread="9.0"/>
                    <measurement group_id="B2" value="36.6" spread="7.0"/>
                    <measurement group_id="B3" value="33.7" spread="8.4"/>
                    <measurement group_id="B4" value="37.0" spread="6.5"/>
                    <measurement group_id="B5" value="27.0" spread="2.2"/>
                    <measurement group_id="B6" value="44.0" spread="8.1"/>
                    <measurement group_id="B7" value="36.3" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White/Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any Adverse Event</title>
        <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A list of all adverse events is reported in the &quot;Other (Non-Serious) Adverse Events&quot; section. Non-serious AEs were not collected during the Individualized Follow-up Period.</description>
        <time_frame>First Treatment Period (FTP): From Visit 3 (Week 0) up to Visit 10 (Week 24); Second Treatment Period (STP): From Visit 10 (Week 24) up to Visit 17 (Week 48); IFUP: up to Visit 26 (Week 104)</time_frame>
        <population>Full Analysis Set (FAS): all participants who had been exposed to the investigational product (IP) irrespective of their compliance to the planned course of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Adverse Event</title>
          <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A list of all adverse events is reported in the &quot;Other (Non-Serious) Adverse Events&quot; section. Non-serious AEs were not collected during the Individualized Follow-up Period.</description>
          <population>Full Analysis Set (FAS): all participants who had been exposed to the investigational product (IP) irrespective of their compliance to the planned course of treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weeks 0-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 24-48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individualized Follow-up Period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With the Indicated Critical Adverse Events (CAEs)</title>
        <description>A CAE=treatment-related (TR) grade (G) &gt;=3 AE on day of infusion (inf.) preventing inf. to be resumed, a TR G 3 bronchospasm during 1 inf., an AE whose severity becomes G 3 for the third time during 1 inf., infections reported as serious, a TR neurological event consistent with progressive multifocal leukoencephalopathy (PML), any malignancy, and any fatal adverse drug reaction. AE severity (assessed as G 1-5) was classified using the Common Terminology Criteria for Adverse Events v3.0: G 1=mild AE; G 2=moderate AE; G 3=severe AE; G 4=life-threatening or disabling AE; G 5=death related to AE.</description>
        <time_frame>FTP: From Visit 3 (Week 0) up to Visit 10 (Week 24); STP: From Visit 10 (Week 24) up to Visit 17 (Week 48); IFUP: up to Visit 26 (Week 104)</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Critical Adverse Events (CAEs)</title>
          <description>A CAE=treatment-related (TR) grade (G) &gt;=3 AE on day of infusion (inf.) preventing inf. to be resumed, a TR G 3 bronchospasm during 1 inf., an AE whose severity becomes G 3 for the third time during 1 inf., infections reported as serious, a TR neurological event consistent with progressive multifocal leukoencephalopathy (PML), any malignancy, and any fatal adverse drug reaction. AE severity (assessed as G 1-5) was classified using the Common Terminology Criteria for Adverse Events v3.0: G 1=mild AE; G 2=moderate AE; G 3=severe AE; G 4=life-threatening or disabling AE; G 5=death related to AE.</description>
          <population>FAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0-24; Influenza</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0-24; Bronchospasm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0-24; Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0-24; Rash pruritic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24-48; any CAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individualized Follow-up Period; any CAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Negative or Unconfirmed Human Anti-human Antibodies (HAHA) in Which Concentrations of Ofa Were Below 500 Nanograms Per Milliliter (ng/ml)</title>
        <description>Participants are checked for negative (or a lack of) HAHA at Baseline, and then throughout the study, to ensure that the investigational product is not causing HAHA development. Participants with concentrations of Ofa that are missing or are above 500 nanograms per milliliter (ng/mL) are considered to have unconfirmed HAHA results.</description>
        <time_frame>Visit 3 (Week 0), Visit 10 (Week 24), Visit 17 (Week 48) or early withdrawal (EW), and Visit 26 (Week 104)</time_frame>
        <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Negative or Unconfirmed Human Anti-human Antibodies (HAHA) in Which Concentrations of Ofa Were Below 500 Nanograms Per Milliliter (ng/ml)</title>
          <description>Participants are checked for negative (or a lack of) HAHA at Baseline, and then throughout the study, to ensure that the investigational product is not causing HAHA development. Participants with concentrations of Ofa that are missing or are above 500 nanograms per milliliter (ng/mL) are considered to have unconfirmed HAHA results.</description>
          <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0; n=8, 8, 2, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24; n=8, 9, 1, 4, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 or EW, negative; n=8, 11, 7, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 or EW, unconfirmed, n=8, 11, 7, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFUP, n=8, 11, 7, 4, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Physical Examination Findings</title>
        <description>The investigator performed the physical examination, which included but was not limited to: general appearance and the following body systems: lymph nodes, mouth and throat, lungs, cardiovascular, abdomen, extremities, muscular-skeletal, neurological (apart from multiple sclerosis [a brain and spinal cord disease]), and skin. All abnormal clinically relevant findings such as vein problems (venous varices), disorder of the vertebral column (vertebropathy), increased hearing loss, post operative mark (scar), and chronic skin disorder with no sweat and itching (anhidrotic eczema) were reported.</description>
        <time_frame>FTP: From Visit 3 (Week 0) up to Visit 10 (Week 24); STP: From Visit 10 (Week 24) up to Visit 17 (Week 48); IFUP: up to Visit 26 (Week 104)</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Physical Examination Findings</title>
          <description>The investigator performed the physical examination, which included but was not limited to: general appearance and the following body systems: lymph nodes, mouth and throat, lungs, cardiovascular, abdomen, extremities, muscular-skeletal, neurological (apart from multiple sclerosis [a brain and spinal cord disease]), and skin. All abnormal clinically relevant findings such as vein problems (venous varices), disorder of the vertebral column (vertebropathy), increased hearing loss, post operative mark (scar), and chronic skin disorder with no sweat and itching (anhidrotic eczema) were reported.</description>
          <population>FAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0-24; Venous varices on legs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0-24; Vertebropathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0-24; Obesitas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0-24; Increased hearing loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0-24; Post operative scar</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0-24; Anhidrotic eczema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24-48; Venous varices on legs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24-48; Vertebropathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24-48; Obesitas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24-48; Acne vulgaris</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24-48; Post operative scar</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFUP; Any physical examination finding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Basophils, Eosinophils, Leukocytes, Monocytes, Lymphocytes, Neutrophils, and Platelet Count at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</title>
        <description>Blood samples of participants were collected for hematology assessment. Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in basophils, eosinophils, leukocytes, monocytes, lymphocytes, neutrophils, and platelets count was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Week 104 for the IFUP minus the value at Baseline.</description>
        <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48); IFUP: Visit 26 (Week 104)</time_frame>
        <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Basophils, Eosinophils, Leukocytes, Monocytes, Lymphocytes, Neutrophils, and Platelet Count at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</title>
          <description>Blood samples of participants were collected for hematology assessment. Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in basophils, eosinophils, leukocytes, monocytes, lymphocytes, neutrophils, and platelets count was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Week 104 for the IFUP minus the value at Baseline.</description>
          <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
          <units>Giga (10^9) per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0-24, Basophils; n=7, 10, 7, 3, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0-24, Eosinophils; n=8, 10, 6, 2, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.05"/>
                    <measurement group_id="O2" value="-0.05" spread="0.13"/>
                    <measurement group_id="O3" value="0.02" spread="0.15"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="-0.23" spread="0.21"/>
                    <measurement group_id="O6" value="0.03" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0-24, Leukocytes; n=8, 10, 7, 3, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.6"/>
                    <measurement group_id="O2" value="0.6" spread="2.4"/>
                    <measurement group_id="O3" value="-0.1" spread="3.3"/>
                    <measurement group_id="O4" value="-0.3" spread="1.6"/>
                    <measurement group_id="O5" value="0.7" spread="5.9"/>
                    <measurement group_id="O6" value="0.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0-24, Lymphocytes; n=8, 10, 7, 3, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="1.03"/>
                    <measurement group_id="O2" value="-0.36" spread="0.67"/>
                    <measurement group_id="O3" value="-0.19" spread="0.78"/>
                    <measurement group_id="O4" value="-0.37" spread="0.31"/>
                    <measurement group_id="O5" value="-0.60" spread="0.79"/>
                    <measurement group_id="O6" value="0.12" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0-24, Monocytes; n=8, 10, 7, 3, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.31"/>
                    <measurement group_id="O2" value="-0.07" spread="0.23"/>
                    <measurement group_id="O3" value="0.00" spread="0.20"/>
                    <measurement group_id="O4" value="0.07" spread="0.06"/>
                    <measurement group_id="O5" value="-0.40" spread="0.17"/>
                    <measurement group_id="O6" value="0.05" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0-24, Neutrophils; n=8, 10, 7, 3, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.9"/>
                    <measurement group_id="O2" value="1" spread="2.2"/>
                    <measurement group_id="O3" value="0" spread="3.8"/>
                    <measurement group_id="O4" value="-0.1" spread="1.5"/>
                    <measurement group_id="O5" value="-0.8" spread="1.7"/>
                    <measurement group_id="O6" value="0.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0-24, Platelets; n=8, 10, 7, 3, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="33.3"/>
                    <measurement group_id="O2" value="10.8" spread="44.0"/>
                    <measurement group_id="O3" value="7.6" spread="39.7"/>
                    <measurement group_id="O4" value="0.3" spread="29.5"/>
                    <measurement group_id="O5" value="5.8" spread="36.2"/>
                    <measurement group_id="O6" value="-4.8" spread="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24-48, Basophils; n=8, 8, 5, 3, 2, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24-48, Eosinophils; n=8, 8, 5, 3, 2, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.05"/>
                    <measurement group_id="O2" value="-0.04" spread="0.16"/>
                    <measurement group_id="O3" value="0.04" spread="0.09"/>
                    <measurement group_id="O4" value="-0.07" spread="0.06"/>
                    <measurement group_id="O5" value="-0.20" spread="0.28"/>
                    <measurement group_id="O6" value="0.03" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24-48, Leukocytes; n=8, 10, 7, 3, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.1"/>
                    <measurement group_id="O2" value="-0.1" spread="1.7"/>
                    <measurement group_id="O3" value="-0.3" spread="1.1"/>
                    <measurement group_id="O4" value="-0.9" spread="0.6"/>
                    <measurement group_id="O5" value="-3.7" spread="1.7"/>
                    <measurement group_id="O6" value="0.9" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24-48, Lymphocytes; n=8, 8, 6, 3, 2, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.36"/>
                    <measurement group_id="O2" value="-0.28" spread="0.47"/>
                    <measurement group_id="O3" value="0.15" spread="0.36"/>
                    <measurement group_id="O4" value="-0.50" spread="0.20"/>
                    <measurement group_id="O5" value="-0.65" spread="0.78"/>
                    <measurement group_id="O6" value="-0.25" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24-48, Monocytes; n=8, 8, 6, 3, 2, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.07"/>
                    <measurement group_id="O2" value="-0.01" spread="0.12"/>
                    <measurement group_id="O3" value="0.02" spread="0.17"/>
                    <measurement group_id="O4" value="0.03" spread="0.06"/>
                    <measurement group_id="O5" value="-0.04" spread="0.28"/>
                    <measurement group_id="O6" value="0.13" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24-48, Neutrophils; n=8, 8, 6, 3, 2, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.2"/>
                    <measurement group_id="O2" value="0.2" spread="1.8"/>
                    <measurement group_id="O3" value="-0.4" spread="1.0"/>
                    <measurement group_id="O4" value="-0.4" spread="0.4"/>
                    <measurement group_id="O5" value="-2.9" spread="1.3"/>
                    <measurement group_id="O6" value="1.0" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24-48, Platelets; n=8, 10, 7, 3, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5" spread="17.3"/>
                    <measurement group_id="O2" value="-16.3" spread="74.2"/>
                    <measurement group_id="O3" value="-10.1" spread="14.7"/>
                    <measurement group_id="O4" value="-13.7" spread="20.6"/>
                    <measurement group_id="O5" value="-34.3" spread="47.3"/>
                    <measurement group_id="O6" value="-11.0" spread="38.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0-104, Basophils; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0-104, Eosinophils; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0-104, Leukocytes; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0-104, Lymphocytes; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0-104, Monocytes; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0-104, Neutrophils; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0-104, Platelets; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.0">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Erythrocyte Count at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</title>
        <description>Blood samples of participants were collected for assessment of erythrocyte count. Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in erythrocyte count was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Visit 26 (Week 104) for the IFUP minus the value at Baseline.</description>
        <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48); IFUP: Visit 26 (Week 104)</time_frame>
        <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Erythrocyte Count at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</title>
          <description>Blood samples of participants were collected for assessment of erythrocyte count. Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in erythrocyte count was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Visit 26 (Week 104) for the IFUP minus the value at Baseline.</description>
          <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
          <units>Pico (10^12) per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24; n=8, 10, 7, 3, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.25"/>
                    <measurement group_id="O2" value="-0.11" spread="0.33"/>
                    <measurement group_id="O3" value="-0.02" spread="0.23"/>
                    <measurement group_id="O4" value="-0.09" spread="0.20"/>
                    <measurement group_id="O5" value="-0.06" spread="0.42"/>
                    <measurement group_id="O6" value="0.07" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48; n=8, 10, 7, 3, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.26"/>
                    <measurement group_id="O2" value="0.12" spread="0.34"/>
                    <measurement group_id="O3" value="0.12" spread="0.25"/>
                    <measurement group_id="O4" value="0.01" spread="0.43"/>
                    <measurement group_id="O5" value="0.06" spread="0.18"/>
                    <measurement group_id="O6" value="0.09" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Hematocrit at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</title>
        <description>Blood samples of participants were collected for hematocrit assessment. Hematocrit is the percentage of blood volume (BV) that is occupied by red blood cells (RBCs). Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in hematocrit was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Visit 26 (Week 104) for the IFUP minus the value at Baseline. Hematocrit is measured as a percentage, i.e., volume (V) of red blood cells per volume of blood.</description>
        <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48); IFUP: Visit 26 (Week 104)</time_frame>
        <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Hematocrit at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</title>
          <description>Blood samples of participants were collected for hematocrit assessment. Hematocrit is the percentage of blood volume (BV) that is occupied by red blood cells (RBCs). Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in hematocrit was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Visit 26 (Week 104) for the IFUP minus the value at Baseline. Hematocrit is measured as a percentage, i.e., volume (V) of red blood cells per volume of blood.</description>
          <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
          <units>Percentage of BV occupied by RBCs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24; n=8, 10, 7, 3, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="0.03"/>
                    <measurement group_id="O2" value="0.01" spread="0.03"/>
                    <measurement group_id="O3" value="-0.01" spread="0.02"/>
                    <measurement group_id="O4" value="-0.02" spread="0.02"/>
                    <measurement group_id="O5" value="0.02" spread="0.04"/>
                    <measurement group_id="O6" value="0.01" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48; n=8, 10, 7, 3, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.02"/>
                    <measurement group_id="O2" value="0.02" spread="0.03"/>
                    <measurement group_id="O3" value="0.00" spread="0.03"/>
                    <measurement group_id="O4" value="0.01" spread="0.05"/>
                    <measurement group_id="O5" value="0.01" spread="0.01"/>
                    <measurement group_id="O6" value="0.02" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Hemoglobin Count at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</title>
        <description>Blood samples of participants were collected for assessment of hemoglobin count. Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in hemoglobin was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Visit 26 (Week 104) for the IFUP minus the value at Baseline.</description>
        <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48); IFUP: Visit 26 (Week 104)</time_frame>
        <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Hemoglobin Count at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</title>
          <description>Blood samples of participants were collected for assessment of hemoglobin count. Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in hemoglobin was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Visit 26 (Week 104) for the IFUP minus the value at Baseline.</description>
          <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
          <units>Millimoles/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24; n=8, 10, 7, 3, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.5"/>
                    <measurement group_id="O2" value="-0.3" spread="0.7"/>
                    <measurement group_id="O3" value="-0.0" spread="0.5"/>
                    <measurement group_id="O4" value="-0.4" spread="0.4"/>
                    <measurement group_id="O5" value="-0.1" spread="0.8"/>
                    <measurement group_id="O6" value="0.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48; n=8, 10, 7, 3, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.5"/>
                    <measurement group_id="O2" value="0.1" spread="0.7"/>
                    <measurement group_id="O3" value="0.2" spread="0.5"/>
                    <measurement group_id="O4" value="-0.3" spread="1.1"/>
                    <measurement group_id="O5" value="0.0" spread="0.3"/>
                    <measurement group_id="O6" value="0.5" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Albumin at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</title>
        <description>Blood samples of participants were collected for assessment of albumin count. Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 104 for the IFUP) in albumin was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Visit 26 (Week 104) for the IFUP minus the value at Baseline.</description>
        <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48); IFUP: VIsit 26 (Week 104)</time_frame>
        <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Albumin at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</title>
          <description>Blood samples of participants were collected for assessment of albumin count. Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 104 for the IFUP) in albumin was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Visit 26 (Week 104) for the IFUP minus the value at Baseline.</description>
          <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
          <units>grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24; n=8, 10, 6, 4, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="2.5"/>
                    <measurement group_id="O2" value="-0.5" spread="2.5"/>
                    <measurement group_id="O3" value="1.3" spread="1.2"/>
                    <measurement group_id="O4" value="-1.6" spread="3.4"/>
                    <measurement group_id="O5" value="-1.2" spread="6.1"/>
                    <measurement group_id="O6" value="2.0" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48; n=8, 11, 7, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="2.5"/>
                    <measurement group_id="O2" value="-0.2" spread="3.1"/>
                    <measurement group_id="O3" value="1.4" spread="3.0"/>
                    <measurement group_id="O4" value="-1.1" spread="5.7"/>
                    <measurement group_id="O5" value="0.4" spread="4.0"/>
                    <measurement group_id="O6" value="1.1" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Alkaline Phosphatase, Aspartate Aminotransferase (AST), and Alanine Transaminase (ALT) at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</title>
        <description>Blood samples of participants were collected for the assessment of alkaline phosphatase, AST, and ALT. Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Visit 26 (Week 104) for the IFUP minus the value at Baseline.</description>
        <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48); IFUP: up to Visit 26 (Week 104)</time_frame>
        <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Alkaline Phosphatase, Aspartate Aminotransferase (AST), and Alanine Transaminase (ALT) at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</title>
          <description>Blood samples of participants were collected for the assessment of alkaline phosphatase, AST, and ALT. Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Visit 26 (Week 104) for the IFUP minus the value at Baseline.</description>
          <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
          <units>Units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24, Alkaline phosphatase; n=8, 10, 6, 4, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="9.0"/>
                    <measurement group_id="O2" value="3.8" spread="11.9"/>
                    <measurement group_id="O3" value="2.7" spread="8.3"/>
                    <measurement group_id="O4" value="13.0" spread="20.2"/>
                    <measurement group_id="O5" value="2.3" spread="10.6"/>
                    <measurement group_id="O6" value="8.8" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, AST; n=8, 10, 6, 4, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="5.1"/>
                    <measurement group_id="O2" value="1.6" spread="6.3"/>
                    <measurement group_id="O3" value="-0.2" spread="3.1"/>
                    <measurement group_id="O4" value="-9.5" spread="28.6"/>
                    <measurement group_id="O5" value="4.3" spread="3.2"/>
                    <measurement group_id="O6" value="-1.0" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, ALT; n=8, 10, 6, 4, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="10.2"/>
                    <measurement group_id="O2" value="4.7" spread="10.0"/>
                    <measurement group_id="O3" value="-1.7" spread="6.4"/>
                    <measurement group_id="O4" value="7.3" spread="24.4"/>
                    <measurement group_id="O5" value="5.3" spread="5.4"/>
                    <measurement group_id="O6" value="0" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, Alkaline phosphatase; n=8, 11, 7, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="10.7"/>
                    <measurement group_id="O2" value="3.1" spread="8.8"/>
                    <measurement group_id="O3" value="9.1" spread="12.6"/>
                    <measurement group_id="O4" value="5.3" spread="17.7"/>
                    <measurement group_id="O5" value="5.7" spread="7.6"/>
                    <measurement group_id="O6" value="12.5" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, AST; n=8, 11, 7, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="2.6"/>
                    <measurement group_id="O2" value="1.5" spread="3.0"/>
                    <measurement group_id="O3" value="0.3" spread="2.5"/>
                    <measurement group_id="O4" value="-13.3" spread="28.5"/>
                    <measurement group_id="O5" value="0.7" spread="4.7"/>
                    <measurement group_id="O6" value="3.3" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, ALT; n=8, 11, 7, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="5.3"/>
                    <measurement group_id="O2" value="0.6" spread="4.7"/>
                    <measurement group_id="O3" value="0.6" spread="7.4"/>
                    <measurement group_id="O4" value="-4.3" spread="9.3"/>
                    <measurement group_id="O5" value="0.7" spread="8.1"/>
                    <measurement group_id="O6" value="8.0" spread="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104, Alkaline phosphatase; n=1,0,0,0,0,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104, AST; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104, ALT; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Bicarbonate, Glucose, Potassium, Sodium, and Urea at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</title>
        <description>Blood samples of participants were collected for the assessment of bicarbonate, glucose, potassium, and urea. Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Visit 26 (Week 104) for the IFUP minus the value at Baseline.</description>
        <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48); IFUP: up to Visit 26 (Week 104)</time_frame>
        <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before consideAfter completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.ring progression to the 700 mg dose.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Bicarbonate, Glucose, Potassium, Sodium, and Urea at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</title>
          <description>Blood samples of participants were collected for the assessment of bicarbonate, glucose, potassium, and urea. Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Visit 26 (Week 104) for the IFUP minus the value at Baseline.</description>
          <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
          <units>millimoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24, Bicarbonate; n=8, 10, 6, 4, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="2.2"/>
                    <measurement group_id="O2" value="-1.1" spread="2.6"/>
                    <measurement group_id="O3" value="-0.6" spread="2.5"/>
                    <measurement group_id="O4" value="1.5" spread="3.2"/>
                    <measurement group_id="O5" value="-2.0" spread="1.3"/>
                    <measurement group_id="O6" value="-0.6" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, Glucose; n=8, 10, 7, 4, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.59"/>
                    <measurement group_id="O2" value="0.39" spread="1.37"/>
                    <measurement group_id="O3" value="0.64" spread="1.23"/>
                    <measurement group_id="O4" value="0.21" spread="0.42"/>
                    <measurement group_id="O5" value="0.08" spread="0.63"/>
                    <measurement group_id="O6" value="-0.22" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, Potassium; n=8, 10, 6, 4, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.35"/>
                    <measurement group_id="O2" value="0.06" spread="0.52"/>
                    <measurement group_id="O3" value="0.03" spread="0.27"/>
                    <measurement group_id="O4" value="-0.63" spread="1.01"/>
                    <measurement group_id="O5" value="-0.20" spread="0.63"/>
                    <measurement group_id="O6" value="-0.00" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, Sodium; n=8, 10, 6, 4, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="2.7"/>
                    <measurement group_id="O2" value="-0.5" spread="2.8"/>
                    <measurement group_id="O3" value="-1.2" spread="1.3"/>
                    <measurement group_id="O4" value="0.5" spread="1.7"/>
                    <measurement group_id="O5" value="0.8" spread="2.1"/>
                    <measurement group_id="O6" value="0.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, Urea; n=8, 10, 6, 4, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.6"/>
                    <measurement group_id="O2" value="-0.8" spread="1.6"/>
                    <measurement group_id="O3" value="0.4" spread="1.5"/>
                    <measurement group_id="O4" value="-0.6" spread="0.8"/>
                    <measurement group_id="O5" value="-0.7" spread="2.1"/>
                    <measurement group_id="O6" value="-0.1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, Bicarbonate; n=8, 11, 7, 4, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="2.9"/>
                    <measurement group_id="O2" value="-0.7" spread="2.8"/>
                    <measurement group_id="O3" value="0.6" spread="1.3"/>
                    <measurement group_id="O4" value="0.6" spread="0.2"/>
                    <measurement group_id="O5" value="1.9" spread="3.1"/>
                    <measurement group_id="O6" value="1.0" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, Glucose; n=8, 10, 7, 4, 2, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.50"/>
                    <measurement group_id="O2" value="0.25" spread="0.95"/>
                    <measurement group_id="O3" value="-0.05" spread="0.51"/>
                    <measurement group_id="O4" value="0.09" spread="0.56"/>
                    <measurement group_id="O5" value="-0.64" spread="0.44"/>
                    <measurement group_id="O6" value="0.27" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, Potassium; n=8, 10, 6, 4, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.21" spread="0.11"/>
                    <measurement group_id="O2" value="4.43" spread="0.44"/>
                    <measurement group_id="O3" value="4.18" spread="0.34"/>
                    <measurement group_id="O4" value="4.23" spread="0.32"/>
                    <measurement group_id="O5" value="3.98" spread="0.10"/>
                    <measurement group_id="O6" value="4.20" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, Sodium; n=8, 11, 7, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="1.6"/>
                    <measurement group_id="O2" value="-0.07" spread="3.1"/>
                    <measurement group_id="O3" value="0.7" spread="1.0"/>
                    <measurement group_id="O4" value="-0.5" spread="3.7"/>
                    <measurement group_id="O5" value="-0.7" spread="1.2"/>
                    <measurement group_id="O6" value="0.8" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, Urea; n=8, 11, 7, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="1.40"/>
                    <measurement group_id="O2" value="-0.05" spread="1.32"/>
                    <measurement group_id="O3" value="-0.19" spread="0.68"/>
                    <measurement group_id="O4" value="-0.30" spread="1.04"/>
                    <measurement group_id="O5" value="1.00" spread="2.20"/>
                    <measurement group_id="O6" value="-0.17" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104, Bicarbonate; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104, Glucose; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104, Potassium; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104, Sodium; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104, Urea; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline (Week 0 for the FTP,Week 24 for the STP, and Week 0 for the IFUP) in Bilirubin and Creatinine at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</title>
        <description>Blood samples of participants were collected for the assessment of bilirubin and creatinine. Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Visit 26 (Week 104) for the IFUP minus the value at Baseline.</description>
        <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48); IFUP: up to Visit 26 (Week 104)</time_frame>
        <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (Week 0 for the FTP,Week 24 for the STP, and Week 0 for the IFUP) in Bilirubin and Creatinine at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</title>
          <description>Blood samples of participants were collected for the assessment of bilirubin and creatinine. Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Visit 26 (Week 104) for the IFUP minus the value at Baseline.</description>
          <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
          <units>Micromoles per liter (Âµmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24, Bilirubin; n=8, 10, 5, 4, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="5.2"/>
                    <measurement group_id="O2" value="-0.0" spread="4.0"/>
                    <measurement group_id="O3" value="1.2" spread="2.2"/>
                    <measurement group_id="O4" value="0.5" spread="4.0"/>
                    <measurement group_id="O5" value="-2.6" spread="3.5"/>
                    <measurement group_id="O6" value="0.3" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, Creatinine; n=8, 10, 6, 4, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="11.8"/>
                    <measurement group_id="O2" value="-0.1" spread="7.6"/>
                    <measurement group_id="O3" value="2.5" spread="4.7"/>
                    <measurement group_id="O4" value="2.5" spread="5.7"/>
                    <measurement group_id="O5" value="-2.9" spread="7.8"/>
                    <measurement group_id="O6" value="-1.2" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, Bilirubin; n=8, 10, 6, 4, 2, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="4.9"/>
                    <measurement group_id="O2" value="-0.1" spread="4.8"/>
                    <measurement group_id="O3" value="1.5" spread="3.5"/>
                    <measurement group_id="O4" value="0.7" spread="3.4"/>
                    <measurement group_id="O5" value="-2.8" spread="1.0"/>
                    <measurement group_id="O6" value="0.6" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, Creatinine; n=8, 11, 7, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="8.7"/>
                    <measurement group_id="O2" value="-1.9" spread="5.3"/>
                    <measurement group_id="O3" value="-0.3" spread="4.1"/>
                    <measurement group_id="O4" value="3.5" spread="6.7"/>
                    <measurement group_id="O5" value="-5.0" spread="6.5"/>
                    <measurement group_id="O6" value="2.0" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104, Bilirubin; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.70">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104, Creatinine; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Immunoglobins at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</title>
        <description>Blood samples of participants were collected for the assessment of antibodies produced by B-cells (immunoglobins): immunoglobulin A, immunoglobin G, and immunoglobin M. Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Visit 26 (Week 104) for the IFUP minus the value at Baseline.</description>
        <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48); IFUP: up to Visit 26 (Week 104)</time_frame>
        <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Immunoglobins at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)</title>
          <description>Blood samples of participants were collected for the assessment of antibodies produced by B-cells (immunoglobins): immunoglobulin A, immunoglobin G, and immunoglobin M. Change from Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) was calculated as the value at Visit 10 (Week 24) for the FTP, the value at Visit 17 (Week 48) for the STP, and the value at Visit 26 (Week 104) for the IFUP minus the value at Baseline.</description>
          <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
          <units>grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24, IGA; n=8, 10, 6, 4, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.16"/>
                    <measurement group_id="O2" value="0.08" spread="0.16"/>
                    <measurement group_id="O3" value="0.40" spread="0.40"/>
                    <measurement group_id="O4" value="-0.07" spread="0.18"/>
                    <measurement group_id="O5" value="0" spread="0.44"/>
                    <measurement group_id="O6" value="0.49" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, IGG; n=8, 10, 6, 4, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.0"/>
                    <measurement group_id="O2" value="-0.1" spread="0.8"/>
                    <measurement group_id="O3" value="1.2" spread="1.0"/>
                    <measurement group_id="O4" value="-0.5" spread="1.0"/>
                    <measurement group_id="O5" value="-0.3" spread="0.9"/>
                    <measurement group_id="O6" value="1.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, IGM; n=8, 10, 6, 4, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.14"/>
                    <measurement group_id="O2" value="-0.13" spread="0.39"/>
                    <measurement group_id="O3" value="-0.19" spread="0.09"/>
                    <measurement group_id="O4" value="0.25" spread="0.25"/>
                    <measurement group_id="O5" value="-0.07" spread="0.19"/>
                    <measurement group_id="O6" value="0.04" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, IGA; n=8, 11, 7, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.24"/>
                    <measurement group_id="O2" value="-0.03" spread="0.39"/>
                    <measurement group_id="O3" value="0.13" spread="0.11"/>
                    <measurement group_id="O4" value="-0.00" spread="0.24"/>
                    <measurement group_id="O5" value="0.05" spread="0.21"/>
                    <measurement group_id="O6" value="0.29" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, IGG; n=8, 11, 7, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.2"/>
                    <measurement group_id="O2" value="0.5" spread="1.6"/>
                    <measurement group_id="O3" value="1.0" spread="0.7"/>
                    <measurement group_id="O4" value="-0.6" spread="1.2"/>
                    <measurement group_id="O5" value="0.2" spread="1.6"/>
                    <measurement group_id="O6" value="1.2" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, IGM; n=8, 11, 7, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.24"/>
                    <measurement group_id="O2" value="-0.21" spread="0.22"/>
                    <measurement group_id="O3" value="-0.18" spread="0.24"/>
                    <measurement group_id="O4" value="-0.24" spread="0.24"/>
                    <measurement group_id="O5" value="-0.40" spread="0.17"/>
                    <measurement group_id="O6" value="-0.13" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104, IGA; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104, IGG; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104, IGM; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline (Week 0 for the FTP and Week 24 for the STP) in Blood Pressure (BP) at Week 24 (FTP) and Week 48 (STP)</title>
        <description>Maximum (systolic) and minimum (diastolic) BP were assessed prior to infusion. Change from Baseline (Week 0 for the FTP and Week 24 for the STP) was calculated as the value at Visit 10 (Week 24) for the FTP and the value at Visit 17 (Week 48) for the STP minus the value at Baseline.</description>
        <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48)</time_frame>
        <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (Week 0 for the FTP and Week 24 for the STP) in Blood Pressure (BP) at Week 24 (FTP) and Week 48 (STP)</title>
          <description>Maximum (systolic) and minimum (diastolic) BP were assessed prior to infusion. Change from Baseline (Week 0 for the FTP and Week 24 for the STP) was calculated as the value at Visit 10 (Week 24) for the FTP and the value at Visit 17 (Week 48) for the STP minus the value at Baseline.</description>
          <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
          <units>millimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24, Diastolic BP; n=8, 10, 7, 4, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="11.2"/>
                    <measurement group_id="O2" value="-2.3" spread="11.1"/>
                    <measurement group_id="O3" value="-5.4" spread="9.7"/>
                    <measurement group_id="O4" value="-3.5" spread="7.2"/>
                    <measurement group_id="O5" value="4.0" spread="4.9"/>
                    <measurement group_id="O6" value="-1.8" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, Systolic BP; n=8, 10, 7, 4, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" spread="19.7"/>
                    <measurement group_id="O2" value="-2.5" spread="12.3"/>
                    <measurement group_id="O3" value="-3.1" spread="14.2"/>
                    <measurement group_id="O4" value="1.5" spread="11.3"/>
                    <measurement group_id="O5" value="1.0" spread="9.0"/>
                    <measurement group_id="O6" value="-6.5" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, Diastolic BP; n=8, 11, 7, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="4.6"/>
                    <measurement group_id="O2" value="2.1" spread="12.0"/>
                    <measurement group_id="O3" value="0.1" spread="7.8"/>
                    <measurement group_id="O4" value="3.0" spread="4.7"/>
                    <measurement group_id="O5" value="3.3" spread="5.8"/>
                    <measurement group_id="O6" value="6.0" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, Systolic BP; n=8, 11, 7, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="14.5"/>
                    <measurement group_id="O2" value="-2.5" spread="13.9"/>
                    <measurement group_id="O3" value="-4.9" spread="8.2"/>
                    <measurement group_id="O4" value="-2.3" spread="7.4"/>
                    <measurement group_id="O5" value="1.7" spread="10.4"/>
                    <measurement group_id="O6" value="4.5" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline (Week 0 for the FTP and Week 24 for the STP) in Pulse Rate at Week 24 (FTP) and Week 48 (STP)</title>
        <description>The pulse rate of each participant was assessed prior to infusion. Change from Baseline (Week 0 for the FTP and Week 24 for the STP) was calculated as the value at Visit 10 (Week 24) for the FTP and the value at Visit 17 (Week 48) for the STP minus the value at Baseline.</description>
        <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48)</time_frame>
        <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (Week 0 for the FTP and Week 24 for the STP) in Pulse Rate at Week 24 (FTP) and Week 48 (STP)</title>
          <description>The pulse rate of each participant was assessed prior to infusion. Change from Baseline (Week 0 for the FTP and Week 24 for the STP) was calculated as the value at Visit 10 (Week 24) for the FTP and the value at Visit 17 (Week 48) for the STP minus the value at Baseline.</description>
          <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24; n=8, 10, 7, 4, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="11.5"/>
                    <measurement group_id="O2" value="1.6" spread="8.4"/>
                    <measurement group_id="O3" value="0.6" spread="10.7"/>
                    <measurement group_id="O4" value="1.3" spread="13.8"/>
                    <measurement group_id="O5" value="2.0" spread="8.0"/>
                    <measurement group_id="O6" value="3.8" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48; n=8, 11, 7, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="9.8"/>
                    <measurement group_id="O2" value="0.4" spread="11.9"/>
                    <measurement group_id="O3" value="-3.0" spread="10.7"/>
                    <measurement group_id="O4" value="-5.5" spread="10.0"/>
                    <measurement group_id="O5" value="-0.3" spread="9.5"/>
                    <measurement group_id="O6" value="8.0" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline (Week 0 for the FTP and Week 24 for the STP) in Temperature at Week 24 (FTP) and Week 48 (STP)</title>
        <description>The temperature of each participant was assessed prior to infusion. Change from Baseline (Week 0 for the FTP and Week 24 for the STP) was calculated as the value at Visit 10 (Week 24) for the FTP and the value at Visit 17 (Week 48) for the STP minus the value at Baseline.</description>
        <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48)</time_frame>
        <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (Week 0 for the FTP and Week 24 for the STP) in Temperature at Week 24 (FTP) and Week 48 (STP)</title>
          <description>The temperature of each participant was assessed prior to infusion. Change from Baseline (Week 0 for the FTP and Week 24 for the STP) was calculated as the value at Visit 10 (Week 24) for the FTP and the value at Visit 17 (Week 48) for the STP minus the value at Baseline.</description>
          <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
          <units>Degrees Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24; n=8, 10, 7, 4, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.5"/>
                    <measurement group_id="O2" value="0.1" spread="0.2"/>
                    <measurement group_id="O3" value="-0.2" spread="0.5"/>
                    <measurement group_id="O4" value="-0.1" spread="0.4"/>
                    <measurement group_id="O5" value="0.3" spread="0.5"/>
                    <measurement group_id="O6" value="-0.3" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48; n=8, 11, 7, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.4"/>
                    <measurement group_id="O2" value="0.1" spread="0.2"/>
                    <measurement group_id="O3" value="0.1" spread="0.5"/>
                    <measurement group_id="O4" value="-0.1" spread="0.2"/>
                    <measurement group_id="O5" value="0.2" spread="0.3"/>
                    <measurement group_id="O6" value="0.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline (Week 0 for the FTP and Week 24 for the STP) in Complement Activation (CH50) at Week 24 (FTP) and Week 48 (STP)</title>
        <description>Blood samples of participants were collected for CH50 prior to and 2 hours after dosing, and the samples were sent to a Central Laboratory for analysis: Bio Analytical Research Corporation (BARC). Change from Baseline (Week 0 for the FTP; Week 24 for the STP) was calculated as the value at Weeks 24 (FTP) and 48 (STP) minus the value at Baseline. Ofa depletes (induces the cell death of) B cells. When Ofa binds to a B cell, it induces complement CH50, which in turn causes cell death via cytotoxicity. Therefore, the CH50 levels were measured to ensure that CH50 was being appropriately activated.</description>
        <time_frame>FTP: Visit 3 (Week 0) and Visit 10 (Week 24); STP: Visit 10 (Week 24) and Visit 17 (Week 48)</time_frame>
        <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (Week 0 for the FTP and Week 24 for the STP) in Complement Activation (CH50) at Week 24 (FTP) and Week 48 (STP)</title>
          <description>Blood samples of participants were collected for CH50 prior to and 2 hours after dosing, and the samples were sent to a Central Laboratory for analysis: Bio Analytical Research Corporation (BARC). Change from Baseline (Week 0 for the FTP; Week 24 for the STP) was calculated as the value at Weeks 24 (FTP) and 48 (STP) minus the value at Baseline. Ofa depletes (induces the cell death of) B cells. When Ofa binds to a B cell, it induces complement CH50, which in turn causes cell death via cytotoxicity. Therefore, the CH50 levels were measured to ensure that CH50 was being appropriately activated.</description>
          <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
          <units>Units per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24; n=8, 7, 0, 4, 2, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="4.1"/>
                    <measurement group_id="O2" value="-7.1" spread="12.9"/>
                    <measurement group_id="O4" value="2.8" spread="9.1"/>
                    <measurement group_id="O5" value="-19.5" spread="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48; n=4, 0, 0, 1, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="7.8"/>
                    <measurement group_id="O2" value="NA">Data were not collected for this cohort.</measurement>
                    <measurement group_id="O4" value="-31.0" spread="0"/>
                    <measurement group_id="O5" value="NA">Data were not collected for this cohort.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of the Indicated Types of Lesions (Ls) Assessed Per Magnetic Resonance Imaging (MRI)</title>
        <description>The MRI scan was performed prior to dosing and could be performed up to 4 days prior to Visits 3 and 10. An IDMC reviewed the data. T1 enhancing Ls are enhanced by gadolinium, are considered representative of disease activity/inflammation, and may signify a relapse. Measurement of these Ls is comparative from visit to visit. &quot;Total T1 enhancing Ls&quot; represent the total of the new T1 enhancing Ls over the entire study period. T2 L measurements measure all Ls on the brain in terms of volume and size, measuring for new or enlarging Ls. T1 hypointensive Ls are areas of permanent damage.</description>
        <time_frame>FTP: From Visit 3 (Week 0) up to Visit 10 (Week 24); STP: From Visit 10 (Week 24) up to Visit 17 (Week 48); IFUP: up to Visit 26 (Week 104)</time_frame>
        <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of the Indicated Types of Lesions (Ls) Assessed Per Magnetic Resonance Imaging (MRI)</title>
          <description>The MRI scan was performed prior to dosing and could be performed up to 4 days prior to Visits 3 and 10. An IDMC reviewed the data. T1 enhancing Ls are enhanced by gadolinium, are considered representative of disease activity/inflammation, and may signify a relapse. Measurement of these Ls is comparative from visit to visit. &quot;Total T1 enhancing Ls&quot; represent the total of the new T1 enhancing Ls over the entire study period. T2 L measurements measure all Ls on the brain in terms of volume and size, measuring for new or enlarging Ls. T1 hypointensive Ls are areas of permanent damage.</description>
          <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24, New (N) T1 enhancing Ls; n=8,11,7,4,4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.35"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="3.06" spread="4.66"/>
                    <measurement group_id="O5" value="23.50" spread="43.0"/>
                    <measurement group_id="O6" value="2.50" spread="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, Total T1 enhancing Ls; n=8,11,7,4,4,4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.35"/>
                    <measurement group_id="O2" value="0.09" spread="0.30"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="3.63" spread="5.02"/>
                    <measurement group_id="O5" value="25.75" spread="46.23"/>
                    <measurement group_id="O6" value="4.50" spread="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, N and/or enlarging T2 Ls; n=8,11,7,4,4,4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.71"/>
                    <measurement group_id="O2" value="0.09" spread="0.30"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="4.00" spread="6.52"/>
                    <measurement group_id="O5" value="25.00" spread="46.03"/>
                    <measurement group_id="O6" value="3.00" spread="4.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, N T1 hypointense Ls; n=8,11,7,4, 4,4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0.27" spread="0.47"/>
                    <measurement group_id="O3" value="0.29" spread="0.49"/>
                    <measurement group_id="O4" value="1.50" spread="3.00"/>
                    <measurement group_id="O5" value="5.00" spread="9.35"/>
                    <measurement group_id="O6" value="0.25" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, N T1 enhancing Ls; n=8,10,7,4,3,4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.35"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0.29" spread="0.76"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0.33" spread="0.58"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, Total T1 enhancing Ls; n=8,10,7,4,3,4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.35"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0.43" spread="1.13"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="3.00" spread="5.20"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, N and/or enlarging T2 Ls; n=8,10,7,4, 3,4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.35"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0.29" spread="0.76"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0.33" spread="0.58"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, N T1 hypointense Ls; n=8,10,7,4,3,4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="3.00" spread="4.36"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104, N T1 enhancing Ls; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104, Total T1 enhancing Ls; n=1, 0, 0, 0, 0,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104, N and /or enlarging T2 Ls; n=1,0,0,0,0,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104, N T1 hypointense Ls; n=1, 0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0">Only one participant in this treatment arm was assessed for this parameter at this time point; thus, the standard deviation cannot be calculated.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O6" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Volume of T2 Lesions at Week 24 and Week 48</title>
        <description>The MRI scan should be performed prior to dosing and can be performed up to 4 days prior to Visits 3 and 10. An IDMC reviewed the data. The volume of T2 lesions was not a cumulative volume, but the volume measured at Visit 10 and Visit 17. T2 lesion measurements measure all lesions on the brain in terms of volume and size, measuring for new lesions or enlarging lesions.</description>
        <time_frame>Visit 10 (Week 24) and Visit 17 (Week 48)</time_frame>
        <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Volume of T2 Lesions at Week 24 and Week 48</title>
          <description>The MRI scan should be performed prior to dosing and can be performed up to 4 days prior to Visits 3 and 10. An IDMC reviewed the data. The volume of T2 lesions was not a cumulative volume, but the volume measured at Visit 10 and Visit 17. T2 lesion measurements measure all lesions on the brain in terms of volume and size, measuring for new lesions or enlarging lesions.</description>
          <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
          <units>millimeters cubed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24; n=8, 11, 7, 3, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7898" spread="8802"/>
                    <measurement group_id="O2" value="10323" spread="8281"/>
                    <measurement group_id="O3" value="17399" spread="11641"/>
                    <measurement group_id="O4" value="11290" spread="11746"/>
                    <measurement group_id="O5" value="12194" spread="18008"/>
                    <measurement group_id="O6" value="15039" spread="8984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48; n=8, 10, 7, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7791" spread="8878"/>
                    <measurement group_id="O2" value="11304" spread="8269"/>
                    <measurement group_id="O3" value="17566" spread="12413"/>
                    <measurement group_id="O4" value="10684" spread="8903"/>
                    <measurement group_id="O5" value="18164" spread="23696"/>
                    <measurement group_id="O6" value="15166" spread="9060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ofa Drug Concentration After the First (Visit 3), Second (Visit 4), Third (Visit 10), and Fourth (Visit 11) Intravenous (i.v.) Infusions</title>
        <description>The peripheral blood for each participant was collected and analyzed for the concentration of the drug in serum. There were four infusions in the study; the third infusion at Visit 10 represents the first infusion of the second treatment period (Weeks 24-48). Data are presented for the predose concentrations.</description>
        <time_frame>Visit 3 (Week 0), Visit 4 (Week 2), Visit 10 (Week 24), and Visit 11 (Week 26). Samples were drawn predose, immediately following the end of infusion, 10 minutes after infusion, 1 hour after infusion, and 2 hours after infusion.</time_frame>
        <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Ofa Drug Concentration After the First (Visit 3), Second (Visit 4), Third (Visit 10), and Fourth (Visit 11) Intravenous (i.v.) Infusions</title>
          <description>The peripheral blood for each participant was collected and analyzed for the concentration of the drug in serum. There were four infusions in the study; the third infusion at Visit 10 represents the first infusion of the second treatment period (Weeks 24-48). Data are presented for the predose concentrations.</description>
          <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
          <units>milligrams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0; n=8, 10, 6, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3" spread="9.65"/>
                    <measurement group_id="O2" value="85.8" spread="53.7"/>
                    <measurement group_id="O3" value="176" spread="24.2"/>
                    <measurement group_id="O4" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                    <measurement group_id="O5" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                    <measurement group_id="O6" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2; n=8, 10, 6, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4" spread="19.9"/>
                    <measurement group_id="O2" value="64.9" spread="67.1"/>
                    <measurement group_id="O3" value="174" spread="187"/>
                    <measurement group_id="O4" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                    <measurement group_id="O5" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                    <measurement group_id="O6" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24; n=0, 0, 0, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O2" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O3" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O4" value="28.9" spread="8.03"/>
                    <measurement group_id="O5" value="43.4" spread="67.9"/>
                    <measurement group_id="O6" value="72.7" spread="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26; n=0, 0, 0, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O2" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O3" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O4" value="21.6" spread="18.5"/>
                    <measurement group_id="O5" value="47.7" spread="76.9"/>
                    <measurement group_id="O6" value="82.4" spread="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Maximum Observed Plasma Concentration (Cmax) After the First (Visit 3), Second (Visit 4), Third (Visit 10), and Fourth (Visit 11) i.v. Infusions</title>
        <description>The peripheral blood for each participant was collected and analyzed for Cmax after the first, second, third, and fourth i.v. infusions. Assessment was performed using the noncompartmental method (this analysis is highly dependent on the estimation of total drug exposure).</description>
        <time_frame>Visit 3 (Week 0), Visit 4, (Week 2), Visit 10 (Week 24), and Visit 11 (Week 26). Samples were drawn predose, immediately following the end of infusion, 10 minutes after infusion, 1 hour after infusion, and 2 hours after infusion.</time_frame>
        <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>The Maximum Observed Plasma Concentration (Cmax) After the First (Visit 3), Second (Visit 4), Third (Visit 10), and Fourth (Visit 11) i.v. Infusions</title>
          <description>The peripheral blood for each participant was collected and analyzed for Cmax after the first, second, third, and fourth i.v. infusions. Assessment was performed using the noncompartmental method (this analysis is highly dependent on the estimation of total drug exposure).</description>
          <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
          <units>milligrams per liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0; n=8, 10, 6, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8" spread="13.1"/>
                    <measurement group_id="O2" value="124" spread="23.6"/>
                    <measurement group_id="O3" value="346" spread="24.0"/>
                    <measurement group_id="O4" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                    <measurement group_id="O5" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                    <measurement group_id="O6" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2; n=8, 10, 6, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7" spread="14.7"/>
                    <measurement group_id="O2" value="157" spread="25.9"/>
                    <measurement group_id="O3" value="452" spread="28.5"/>
                    <measurement group_id="O4" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                    <measurement group_id="O5" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                    <measurement group_id="O6" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24; n=0, 0, 0, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O2" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O3" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O4" value="33.2" spread="13.7"/>
                    <measurement group_id="O5" value="137" spread="40.7"/>
                    <measurement group_id="O6" value="312" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26; n=0, 0, 0, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O2" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O3" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O4" value="43.5" spread="25.2"/>
                    <measurement group_id="O5" value="210" spread="54.1"/>
                    <measurement group_id="O6" value="416" spread="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Time Point (AUC(0-t)) After the First (Visit 3), Second (Visit 4), Third (Visit 10), and Fourth (Visit 11) i.v. Infusions</title>
        <description>The peripheral blood for each participant was collected and analyzed to estimate the area under the plasma concetration-time curve, AUC(0-t), and was assessed using the non-compartmental method.</description>
        <time_frame>Visit 3 (Week 0), Visit 4 (Week 2), Visit 10 (Week 24), and Visit 11 (Week 26). Samples were drawn predose, immediately following the end of infusion, 10 minutes after infusion, 1 hour (hr) after infusion, and 2 hours after infusion.</time_frame>
        <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>The Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Time Point (AUC(0-t)) After the First (Visit 3), Second (Visit 4), Third (Visit 10), and Fourth (Visit 11) i.v. Infusions</title>
          <description>The peripheral blood for each participant was collected and analyzed to estimate the area under the plasma concetration-time curve, AUC(0-t), and was assessed using the non-compartmental method.</description>
          <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
          <units>Millgram hour per liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0; n=8, 10, 6, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153" spread="19.4"/>
                    <measurement group_id="O2" value="498" spread="18.6"/>
                    <measurement group_id="O3" value="1528" spread="20.7"/>
                    <measurement group_id="O4" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                    <measurement group_id="O5" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                    <measurement group_id="O6" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2; n=8, 10, 6, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15559" spread="34.4"/>
                    <measurement group_id="O2" value="63165" spread="40.6"/>
                    <measurement group_id="O3" value="225876" spread="30.4"/>
                    <measurement group_id="O4" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                    <measurement group_id="O5" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                    <measurement group_id="O6" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24; n=0, 0, 0, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O2" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O3" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O4" value="123" spread="8.6"/>
                    <measurement group_id="O5" value="624" spread="32.7"/>
                    <measurement group_id="O6" value="1347" spread="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26; n=0, 0, 0, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O2" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O3" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O4" value="12763" spread="29.3"/>
                    <measurement group_id="O5" value="71041" spread="54.9"/>
                    <measurement group_id="O6" value="217757" spread="44.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Cmax (Tmax) After the First (Visit 3), Second (Visit 4), Third (Visit 10), and Fourth (Visit 11) i.v. Infusions</title>
        <description>The peripheral blood for each participant was collected and analyzed for tmax.</description>
        <time_frame>Visit 3 (Week 0), Visit 4 (Week 2),Visit 10 (Week 24), and Visit 11 (Week 26). Samples were drawn predose, immediately following the end of infusion, 10 minutes after infusion, 1 hour after infusion, and 2 hours after infusion.</time_frame>
        <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Cmax (Tmax) After the First (Visit 3), Second (Visit 4), Third (Visit 10), and Fourth (Visit 11) i.v. Infusions</title>
          <description>The peripheral blood for each participant was collected and analyzed for tmax.</description>
          <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0; n=8, 10, 6, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.33" lower_limit="4.00" upper_limit="8.60"/>
                    <measurement group_id="O2" value="5.88" lower_limit="4.17" upper_limit="7.67"/>
                    <measurement group_id="O3" value="6.00" lower_limit="5.17" upper_limit="9.42"/>
                    <measurement group_id="O4" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                    <measurement group_id="O5" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                    <measurement group_id="O6" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2; n=8, 10, 6, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.25" lower_limit="3.42" upper_limit="5.58"/>
                    <measurement group_id="O2" value="4.33" lower_limit="3.52" upper_limit="6.13"/>
                    <measurement group_id="O3" value="3.83" lower_limit="3.67" upper_limit="4.50"/>
                    <measurement group_id="O4" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                    <measurement group_id="O5" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                    <measurement group_id="O6" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24; n=0, 0, 0, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O2" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O3" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O4" value="4.42" lower_limit="4.08" upper_limit="6.00"/>
                    <measurement group_id="O5" value="6.00" lower_limit="4.17" upper_limit="6.92"/>
                    <measurement group_id="O6" value="6.54" lower_limit="4.13" upper_limit="8.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26; n=0, 0, 0, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O2" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O3" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O4" value="3.67" lower_limit="3.58" upper_limit="6.00"/>
                    <measurement group_id="O5" value="5.17" lower_limit="4.08" upper_limit="5.50"/>
                    <measurement group_id="O6" value="4.50" lower_limit="3.75" upper_limit="5.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance of Ofa Over the Course of Weeks 0-2 and 24-26</title>
        <description>The peripheral blood for each participant was collected and analyzed for clearance. Clearance is the measure of efficiency with which a drug is irreversibly removed form the body. The average clearance over the course of Weeks 0-2 and 24-26 is reported.</description>
        <time_frame>Weeks 0-2 and 24-26</time_frame>
        <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance of Ofa Over the Course of Weeks 0-2 and 24-26</title>
          <description>The peripheral blood for each participant was collected and analyzed for clearance. Clearance is the measure of efficiency with which a drug is irreversibly removed form the body. The average clearance over the course of Weeks 0-2 and 24-26 is reported.</description>
          <population>FAS. Only those participants contributing data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
          <units>liters per hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weeks 0-2; n=8, 10, 6, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.006" spread="34.2"/>
                    <measurement group_id="O2" value="0.005" spread="41.0"/>
                    <measurement group_id="O3" value="0.003" spread="30.8"/>
                    <measurement group_id="O4" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                    <measurement group_id="O5" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                    <measurement group_id="O6" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 24-26; n=0, 0, 0, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O2" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O3" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O4" value="0.008" spread="29.5"/>
                    <measurement group_id="O5" value="0.004" spread="54.4"/>
                    <measurement group_id="O6" value="0.03" spread="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Volume of Distribution at Steady State (Vss) of Ofatumumab Over the Course of Weeks 0-2 and 24-26</title>
        <description>The peripheral blood for each participant was collected and analyzed for Vss. The average Vss over the course of Weeks 0-2 and 24-26 is reported.</description>
        <time_frame>Weeks 0-2 and 24-26</time_frame>
        <population>FAS. Only those participants who contributed data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>The Volume of Distribution at Steady State (Vss) of Ofatumumab Over the Course of Weeks 0-2 and 24-26</title>
          <description>The peripheral blood for each participant was collected and analyzed for Vss. The average Vss over the course of Weeks 0-2 and 24-26 is reported.</description>
          <population>FAS. Only those participants who contributed data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
          <units>liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weeks 0-2; n=8, 10, 6, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" spread="20.4"/>
                    <measurement group_id="O2" value="2.61" spread="42.0"/>
                    <measurement group_id="O3" value="2.19" spread="21.3"/>
                    <measurement group_id="O4" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                    <measurement group_id="O5" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                    <measurement group_id="O6" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 24-26; n=0, 0, 0, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O2" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O3" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O4" value="2.74" spread="6.54"/>
                    <measurement group_id="O5" value="2.20" spread="68.0"/>
                    <measurement group_id="O6" value="2.15" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half Life (t1/2) of Ofatumumab in the Terminal Elimination Phase Over the Course of Weeks 0-2 and 24-26</title>
        <description>The peripheral blood for each participant was collected and analyzed for half life. Half life is defined as the period of time required for the amount of drug in the body to be reduced by half. The average t1/2 over the course of Weeks 0-2 and 24-26 is reported.</description>
        <time_frame>Weeks 0-2 and 24-26</time_frame>
        <population>FAS. Only those participants who contributed data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
            <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
          </group>
          <group group_id="O2">
            <title>300 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
          </group>
          <group group_id="O3">
            <title>700 mg Ofa/Matching Placebo</title>
            <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo/100 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose.</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo/300 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose.</description>
          </group>
          <group group_id="O6">
            <title>Matching Placebo/700 mg Ofa</title>
            <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Half Life (t1/2) of Ofatumumab in the Terminal Elimination Phase Over the Course of Weeks 0-2 and 24-26</title>
          <description>The peripheral blood for each participant was collected and analyzed for half life. Half life is defined as the period of time required for the amount of drug in the body to be reduced by half. The average t1/2 over the course of Weeks 0-2 and 24-26 is reported.</description>
          <population>FAS. Only those participants who contributed data at the indicated time points were analyzed (reflected by &quot;n=&quot; in the category titles).</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weeks 0-2; n=8, 10, 6, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246" spread="16.1"/>
                    <measurement group_id="O2" value="331" spread="35.2"/>
                    <measurement group_id="O3" value="452" spread="28.4"/>
                    <measurement group_id="O4" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                    <measurement group_id="O5" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                    <measurement group_id="O6" value="NA">Ofa concentrations were only measured in Arms 1-3 during Treatment Period 1. Participants in Arms 4-6 received placebo during Treatment Period 1.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 24-26; n=0, 0, 0, 4, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O2" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O3" value="NA">Ofa concentrations were only measured in Arms 4-6 during Treatment Period 2. Participants in Arms 1-3 received placebo during Treatment Period 2.</measurement>
                    <measurement group_id="O4" value="241" spread="23.6"/>
                    <measurement group_id="O5" value="342" spread="16.3"/>
                    <measurement group_id="O6" value="453" spread="49.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs) and non-serious AEs are reported for both the first period (FP; Weeks 0-24) and the second period (SP; Weeks 24-48). SAEs were collected during the IFUP (collected/reported up to Week 104); however, non-serious AEs were not.</time_frame>
      <desc>The duration of B-cell depletion observed following ofatumumab administration makes attribution of an SAE/AE in the SP to placebo versus ofatumumab difficult. Because it may not be appropriate to ascribe events reported in the SP to placebo, SAEs/AEs are reported by treatment sequence rather than by each individual treatment received.</desc>
      <group_list>
        <group group_id="E1">
          <title>100 Milligrams (mg) Ofatumumab (Ofa)/Matching Placebo</title>
          <description>Ofa was administered as two doses of 100 mg via intravenous (iv) infusions separated by 2 weeks (wks) during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An Independent Data Monitoring Committee (IDMC) evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
        </group>
        <group group_id="E2">
          <title>300 mg Ofa/Matching Placebo</title>
          <description>Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
        </group>
        <group group_id="E3">
          <title>700 mg Ofa/Matching Placebo</title>
          <description>Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the first 24-wk treatment period. Matching placebo was administered as two iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
        </group>
        <group group_id="E4">
          <title>Matching Placebo/100 mg Ofa</title>
          <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 100 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 100 mg dose before considering progression to the 300 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
        </group>
        <group group_id="E5">
          <title>Matching Placebo/300 mg Ofa</title>
          <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 300 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. An IDMC evaluated the safety data at Week 4 for participants receiving the 300 mg dose before considering progression to the 700 mg dose. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
        </group>
        <group group_id="E6">
          <title>Matching Placebo/700 mg Ofa</title>
          <description>Matching placebo was administered as two iv infusions separated by 2 wks during the first 24-wk treatment period. Ofa was administered as two doses of 700 mg via iv infusions separated by 2 wks during the second 24-wk treatment period. After completing Week 48 of the second treatment period or withdrawing from the study for any reason, participants entered an Individualized Follow-up Period (IFUP) in which they were monitored for B cell and IgG normalization until individual study termination.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal sensation in eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Tonsilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>False positive laboratory result</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia facial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pharyngeal edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pruritus generalized</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rash generalized</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Bartholin's cyst removal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Antibiotic prophylaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

